Clinical Trial Update: Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating pembrolizumab and disitamab vedotin in HER2-expressing metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Colorectal Neoplasms | Phase 2 | Status: UNKNOWN